Hikma Pharmaceuticals

Hikma Pharmaceuticals, a UK-based Pharmaceutical Preparation Manufacturing company, reported estimated total carbon emissions of approximately 863.1 million kg CO2e in 2025. This includes about 10.4 million kg CO2e from Scope 1 emissions, 1.5 million kg CO2e from Scope 2 emissions, and 851.2 million kg CO2e from Scope 3 emissions. Their Scope 3 emissions are primarily driven by purchased goods and services, accounting for approximately 651 million kg CO2e.

Looking back, in 2024, the company's estimated total emissions were approximately 860.7 million kg CO2e. This comprised around 10.4 million kg CO2e in Scope 1 emissions, 1.5 million kg CO2e in Scope 2 emissions, and 848.8 million kg CO2e in Scope 3 emissions. In 2023, total estimated emissions were approximately 837 million kg CO2e, with about 43.8 million kg CO2e from Scope 1 and approximately 83.5 million kg CO2e from location-based Scope 2 emissions.

Hikma Pharmaceuticals has set a near-term target to reduce its Scope 1 and Scope 2 GHG emissions by 25% by 2030, using a 2020 baseline. Additionally, the company aims to achieve net zero emissions by 2050 for Scope 1 and Scope 2 emissions. The company has previously reported a 4% decrease in combined Scope 1 and Scope 2 GHG emissions between 2017 and 2020. All emissions and climate commitment data are directly from Hikma Pharmaceuticals PLC.